Literature DB >> 33994735

Molecular Signatures of Gynecological Cancers: Clinicians Perspective.

T S Shylasree1, Bansal Richa1, Gurram Lavanya1, Seema Gulia1.   

Abstract

Large-scale molecular profiling and DNA sequencing has revolutionized cancer research. Precision medicine is a rapidly developing area in cancer care but it is not uniformly applied across different tumor types. Biomarker-based therapy is associated with improved outcomes, both in terms of progression-free survival and overall survival. Comprehensive genomic profiling (CGP) uses next-generation sequencing to analyze the complete coding sequence of hundreds of genes from a small amount of tissue. Genes included in these assays are those associated with cancer development or have diagnostic, prognostic, familial, or therapeutic implications Genomic profiling is emerging as a clinically viable tool to personalize patient's treatment. This article discusses how the insights gained through CGP can impact treatment plan in common gynecological cancers. © Indian Association of Surgical Oncology 2021.

Entities:  

Keywords:  Genomic profiling; Gynecological cancers; Precision medicine; The Cancer Genome Atlas (TCGA)

Year:  2021        PMID: 33994735      PMCID: PMC8119522          DOI: 10.1007/s13193-020-01271-8

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  63 in total

1.  Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.

Authors:  David M Gershenson; Charlotte C Sun; Revathy B Iyer; Anais L Malpica; John J Kavanagh; Diane C Bodurka; Kathleen Schmeler; Michael Deavers
Journal:  Gynecol Oncol       Date:  2012-03-06       Impact factor: 5.482

2.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Authors:  Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean Jacques Grob; Vanna Chiarion Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymyr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Michelle Casey; Daniele Ouellet; Anne-Marie Martin; Ngocdiep Le; Kiran Patel; Keith Flaherty
Journal:  N Engl J Med       Date:  2014-09-29       Impact factor: 91.245

3.  Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.

Authors:  Aline Talhouk; Melissa K McConechy; Samuel Leung; Winnie Yang; Amy Lum; Janine Senz; Niki Boyd; Judith Pike; Michael Anglesio; Janice S Kwon; Anthony N Karnezis; David G Huntsman; C Blake Gilks; Jessica N McAlpine
Journal:  Cancer       Date:  2017-01-06       Impact factor: 6.860

4.  Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab.

Authors:  Alessandro D Santin; Stefania Bellone; Natalia Buza; Jungmin Choi; Peter E Schwartz; Joseph Schlessinger; Richard P Lifton
Journal:  Clin Cancer Res       Date:  2016-08-02       Impact factor: 12.531

Review 5.  Advances in understanding cancer genomes through second-generation sequencing.

Authors:  Matthew Meyerson; Stacey Gabriel; Gad Getz
Journal:  Nat Rev Genet       Date:  2010-10       Impact factor: 53.242

6.  Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.

Authors:  David M Gershenson; Diane C Bodurka; Robert L Coleman; Karen H Lu; Anais Malpica; Charlotte C Sun
Journal:  J Clin Oncol       Date:  2017-02-21       Impact factor: 44.544

7.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

Authors:  Garrett M Frampton; Alex Fichtenholtz; Geoff A Otto; Kai Wang; Sean R Downing; Jie He; Michael Schnall-Levin; Jared White; Eric M Sanford; Peter An; James Sun; Frank Juhn; Kristina Brennan; Kiel Iwanik; Ashley Maillet; Jamie Buell; Emily White; Mandy Zhao; Sohail Balasubramanian; Selmira Terzic; Tina Richards; Vera Banning; Lazaro Garcia; Kristen Mahoney; Zac Zwirko; Amy Donahue; Himisha Beltran; Juan Miguel Mosquera; Mark A Rubin; Snjezana Dogan; Cyrus V Hedvat; Michael F Berger; Lajos Pusztai; Matthias Lechner; Chris Boshoff; Mirna Jarosz; Christine Vietz; Alex Parker; Vincent A Miller; Jeffrey S Ross; John Curran; Maureen T Cronin; Philip J Stephens; Doron Lipson; Roman Yelensky
Journal:  Nat Biotechnol       Date:  2013-10-20       Impact factor: 54.908

8.  Prognostic factors in epithelial ovarian cancer: A population-based study.

Authors:  Lin-Chau Chang; Chih-Fen Huang; Mei-Shu Lai; Li-Jiuan Shen; Fe-Lin Lin Wu; Wen-Fang Cheng
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

9.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Robert L Coleman; Amit M Oza; Domenica Lorusso; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Andrew Clamp; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Jesus Garcia-Donas; Elizabeth M Swisher; Anne Floquet; Gottfried E Konecny; Iain A McNeish; Clare L Scott; Terri Cameron; Lara Maloney; Jeff Isaacson; Sandra Goble; Caroline Grace; Thomas C Harding; Mitch Raponi; James Sun; Kevin K Lin; Heidi Giordano; Jonathan A Ledermann
Journal:  Lancet       Date:  2017-09-12       Impact factor: 79.321

10.  Therapeutic options for mucinous ovarian carcinoma.

Authors:  Kylie L Gorringe; Dane Cheasley; Matthew J Wakefield; Georgina L Ryland; Prue E Allan; Kathryn Alsop; Kaushalya C Amarasinghe; Sumitra Ananda; David D L Bowtell; Michael Christie; Yoke-Eng Chiew; Michael Churchman; Anna DeFazio; Sian Fereday; C Blake Gilks; Charlie Gourley; Alison M Hadley; Joy Hendley; Sally M Hunter; Scott H Kaufmann; Catherine J Kennedy; Martin Köbel; Cecile Le Page; Jason Li; Richard Lupat; Orla M McNally; Jessica N McAlpine; Jan Pyman; Simone M Rowley; Carolina Salazar; Hugo Saunders; Timothy Semple; Andrew N Stephens; Niko Thio; Michelle C Torres; Nadia Traficante; Magnus Zethoven; Yoland C Antill; Ian G Campbell; Clare L Scott
Journal:  Gynecol Oncol       Date:  2020-01-02       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.